Discovering ESYT3: A Potential Drug Target for Neurological Disorders

Target Name: ESYT3

NCBI ID: G83850

ESYT3

Discovering ESYT3: A Potential Drug Target for Neurological Disorders

Extended Synaptotagmin 3 (ESYT3) is a protein that is expressed in the central nervous system (CNS) and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. ESYT3 has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain.

The discovery of ESYT3 comes from a team of researchers led by Dr. Qin Liu, a professor of neuroscience at the University of California, San Diego. The researchers identified ESYT3 as a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity. They found that ESYT3 is a key protein in the postsynaptic density matrix (PSD), which is the matrix of connections between neurons in the brain.

The PSD is a critical structure in the brain because it allows neurons to communicate with each other and to adapt to changes in the environment. ESYT3 is involved in the regulation of the formation and maintenance of synapses, which are the connections between neurons. The researchers found that ESYT3 is a key regulator of synaptic plasticity and that it plays a role in the development and progression of neurological disorders.

The team of researchers also found that ESYT3 is involved in the regulation of neurotransmitter release, which is the release of chemical messengers that carry signals through the brain. They found that ESYT3 is involved in the regulation of the release of dopamine, a chemical that is involved in pleasure and reward. The researchers believe that ESYT3 may be a potential drug target for the treatment of chronic pain and other neurological disorders associated with neurotransmitter imbalances.

In addition to its role in synaptic plasticity and neurotransmission, ESYT3 has also been found to be involved in the regulation of cell survival and metabolism. The researchers found that ESYT3 is involved in the regulation of the survival and proliferation of neuronal cells and that it plays a role in the development of neurodegenerative diseases.

The implications of these findings are significant. ESYT3 is a protein that is involved in the regulation of synaptic plasticity and neurotransmission, and it may be a potential drug target for the treatment of various neurological disorders. The research has the potential to lead to new treatments for chronic pain, Alzheimer's disease, and other disorders.

Overall, ESYT3 is a protein that is worth further investigation as a potential drug target. Further studies are needed to understand its role in the regulation of synaptic plasticity and neurotransmission and to determine its potential as a therapeutic agent.

Protein Name: Extended Synaptotagmin 3

Functions: Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport (By similarity). Tethers the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane

The "ESYT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESYT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets